Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials

Inhibition of the human 2-oxoglutarate (2OG) dependent hypoxia inducible factor (HIF) prolyl hydroxylases (human PHD1–3) causes upregulation of HIF, thus promoting erythropoiesis and is therefore of therapeutic interest. We describe cellular, biophysical, and biochemical studies comparing four PHD i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeh, Tzu-Lan, Leissing, Thomas M., Abboud, Martine I., Thinnes, Cyrille C., Atasoylu, Onur, Holt-Martyn, James P., Zhang, Dong, Tumber, Anthony, Lippl, Kerstin, Lohans, Christopher T., Leung, Ivanhoe K. H., Morcrette, Helen, Clifton, Ian J., Claridge, Timothy D. W., Kawamura, Akane, Flashman, Emily, Lu, Xin, Ratcliffe, Peter J., Chowdhury, Rasheduzzaman, Pugh, Christopher W., Schofield, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Royal Society of Chemistry 2017
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802278/
https://www.ncbi.nlm.nih.gov/pubmed/29435217
http://dx.doi.org/10.1039/c7sc02103h

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802278/
https://www.ncbi.nlm.nih.gov/pubmed/29435217
http://dx.doi.org/10.1039/c7sc02103h

Ejemplares similares